- Home
- MNPR vs TLS Comparison
MNPR vs TLS Comparison
Compare MNPR & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | TLS |
|---|---|---|
| Founded | 2014 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.9M | 317.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNPR | TLS |
|---|---|---|
| Price | $55.74 | $4.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $101.42 | $7.75 |
| AVG Volume (30 Days) | 150.5K | ★ 687.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $108,272,000.00 |
| Revenue This Year | N/A | $52.26 |
| Revenue Next Year | N/A | $19.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.06 | $1.83 |
| 52 Week High | $105.00 | $8.36 |
Technical Indicators
Market Signals| Indicator | MNPR | TLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 42.28 |
| Support Level | $56.15 | $3.82 |
| Resistance Level | $61.30 | $4.73 |
| Average True Range (ATR) | 3.32 | 0.22 |
| MACD | 0.75 | 0.06 |
| Stochastic Oscillator | 53.45 | 41.09 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.